Regeneron Pharmaceuticals
Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal
October 14, 2016Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD
Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …
Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials
May 3, 2016Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III
Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …
Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics
Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
October 13, 2026
Tridem begins phase Ib trial of Parkinson’s disease vaccine
October 13, 2026
Trio become latest Symbiosis commercial additions
October 12, 2026
UK immunoglobulin supply faces growing pressure, report warns
October 12, 2026
